BackgroundChimeric antigen receptor (CAR) T-cell therapy represents the most advanced immunotherapy against relapsed/refractory B cell malignancies. While cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are distinctive. known CAR T-cell acute adverse events. hematological toxicity has been increasingly reported. https://www.johnperformance.com/product-category/gift-cards/